DAG and its analogues have long been known to activate RasGRP1 in T and B cells [93,94], and the treatment of B cell lymphoma-derived cell lines with DAG analogues promoted apoptosis [94,95]. Here, RASGRP1 is linked to B-cell non-Hodgkin lymphoma.